ANN ARBOR, Mich., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has created and seeks to fill two new senior-level genetic engineering positions within its U.S. based research and development team. These new roles will expand and strengthen the research team’s capabilities in order to accelerate the pace of development
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the la
ANN ARBOR, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Adviso